DRKS00007787进行中（未招募）2 期
Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. external beam radiotherapy alone in the treatment of advanced castration resistant prostate carcinoma with limited bone metastases - a-RT
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- Male
入选标准
- •1. Has provided written informed consent. Subjects must be able to understand and be willing to sign the written informed consent form (ICF). A signed ICF must be appropriately obtained prior to the conduct of the any trial- specific procedure. Enrollment (entry) in the study is defined as the signing of the informed consent. Age = 18 and = 85 years
- •2. Patients with progressive castration resistant prostate cancer (CRPC) with 1-5 bone metastases for whom Radium-223 dichloride constitutes first-line cytostatic treatment
- •3. Primary tumor (and its local recurrence, if applicable) controlled by effective local treatment
- •4. If diagnosed, pelvic lymph node metastases controlled by effective local treatment
- •5. At least 1 not previously locally treated skeletal metastasis on bone scan without non-bone distant metastases (e.g. lung, liver, and/or brain metastases) and without pathologically enlarged lymph nodes above the pelvis
- •6. Progressive disease is defined either by:
- •- The appearance of new bone lesions. If progression is based on new lesion(s) on bone scan only without an increase in prostate specific antigen (PSA), PSA values from 3 assessments within the last 6 months must be provided; OR
- •- In the absence of new bone lesions by 2 consecutive increases in serum PSA over previous reference value, which should not be more than 6 months before screening, each measured at least 1 week apart with the last PSA =5 ng/mL
- •7. Life expectancy of at least 6 months.
- •8. Zubrod (WHO/ECOG) Performance Status (PS) 0 or 1
- •9. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of therapy:
- •- Hemoglobin > 10.0 g/dl
- •- Absolute neutrophil count (ANC) >1,500/µl
- •- Platelet count >100,000/µl
- •- Total bilirubin < 1.5 times the institutional upper limit of normal (ULN)
- •- ALT and AST < 2.5 x institutional upper limit of normal (ULN)
- •- Serum creatinine < 2 x upper limit of normal.
- •10. Patient has or has had symptoms (e. g. pain or micro-fractions) from bone metastases
排除标准
- •Excluded medical conditions:
- •1. More than 5 not previously locally treated bone metastases as diagnosed by bone scintigraphy;
- •2. Visceral or lymph node metastases above the pelvis as assessed by computed tomography (CT) (or other imaging modality) ;
- •3. History of HIV infection or chronic hepatitis B or C
- •4. Active clinically serious infections (> grade 2 NCI-CTC version 4.03)
- •5. History of organ allograft
- •6. Patients undergoing renal dialysis
- •7. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study if not in complete remission for at least 5 years since date of diagnosis treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- •8. Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results
- •9. Imminent or history of spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI)
- •10. Any other serious illness or medical condition, such as but not limited to:
- •- Cardiac failure New York Heart Association (NYHA) III or IV
- •- Crohn’s disease or ulcerative colitis
- •- Bone marrow dysplasia
- •11. Fecal incontinence
- •12. Any condition that is unstable or could jeopardize the safety of the patient and his compliance in the study
- •13. Known allergy to Radium-223 dichloride (i.e. to active substance or one of the constituents)
- •Excluded therapies and medications, previous and concomitant:
- •1. Anticancer chemo- or targeted therapy for CRPC (e.g. docetaxel or cabazitaxel)
- •2. Radiotherapy for prostate cancer manifestations other than study treatment if not given with curative intent to prostate fossa and/or pelvic lymph nodes
- •3. Major surgery within 4 weeks of study entry.
- •4. Systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or radium-223 dichloride) for the treatment of bone metastases
- •5. Autologous bone marrow transplant or stem cell rescue within 4 months of study entry
- •6. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator; however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study entry or during the study]
- •7. Investigational drug therapy outside of this trial during or within 4 weeks of study entry
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, open-label study to assess the efficacy and safety of lenalidomide in combination with cetuximab in pretreated subjects with KRAS mutant metastatic colorectal cancer - NDPretreated subjects with KRAS mutant metastatic colorectal cancer.MedDRA version: 12.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2009-012665-61-ITCelgene Corporation220
进行中（未招募）
2 期
A phase 2 open label study to assess the efficacy and safety of beta-glucuronidase enzyme replacement therapy in Japanese patients with mucopolysaccharidosis type VII, Sly diseaseJPRN-jRCT2051190088Hamazaki Takashi3
招募中
1 期
Tusamitamab ravtansine in NSQ NSCLC participants with negative or moderate CEACAM5 expression tumors and high circulating CEAon-squamous non-small-cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-004423-32-FRSanofi Aventis Recherche & Développement45
招募中
2 期
Tusamitamab ravtansine in NSQ NSCLC participants with negative or moderate CEACAM5 expression tumors and high circulating CEAJPRN-jRCT2011220001Tomoyuki Tanaka38
进行中（未招募）
1 期
Tusamitamab ravtansine in NSQ NSCLC participants with negative or moderate CEACAM5 expression tumors and high circulating CEAEUCTR2021-004423-32-ESSanofi Aventis Recherche & Développement45